YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Wall Street has offered mixed returns in the third quarter of the year, with the S&P 500 offering about 5.3% gains, the Nasdaq-100 also delivering about 5% gains, the Dow Jones losing about 0.1%, and the small-cap index Russell 2000 fallin…
Cathie Wood’s Ark Invest boosted its technology, biotechnology, and space exposure last week, led by purchases of more than 51K shares of Meta Platforms (META [https://seekingalpha.com/symbol/META]) worth $38.2M and roughly 360K shares of…
[Bitcoin 2022 Conference Draws Cryptocurrency Industry Professionals And Investors To Miami] Marco Bello/Getty Images News Cathie Wood’s Ark Invest leaned further into high-growth themes, including space, fintech, crypto, and biotechnology…
Wall Street delivered an upbeat August. The S&P 500 advanced more than 2.5% in August, while the Nasdaq gained more than 3%. The Dow climbed about 1.3% for the month. However, Wall Street closed the month on a weaker note as renewed U.S.-I…
A photo of Cathie Wood by Caroline Wood via Wikimedia Commons and resized Investment managers used to be hard to find. We had Barron's on Saturdays and the Wall Street Journal during the week. And for those with a technical analysis bent,…
Cathie Wood’s ARK Invest’s largest purchase during July 20-24 was Tesla (TSLA [https://seekingalpha.com/symbol/TSLA]), with the firm acquiring an additional $52.7M stake after a steep sell-off post weaker-than-expected Q2 earnings report.…
If you're keeping an eye on gene-editing specialist CRISPR Therapeutics (NASDAQ: CRSP), you probably already know the up-and-coming biopharmaceutical outfit is a favorite of Ark Investment Management's CEO and chief stock picker, Cathie Wo…
Quick Read ARKG's concentrated, active bet on pre-revenue biotech gained 32% YTD but lost 13 more percentage points than GNOM over the past five years. ARKG's $1.4 billion in assets versus GNOM's $75 million gives larger investors meaningf…
Key Points The biotech has a strong pipeline and is growing its revenue. In June, the FDA approved Ionis's drug, Tryngolza, to treat severe hypertriglyceridemia. The new approval expands the drug's target market to more than 3 million pati…
Key Points On July 8, the Ark Genomic Revolution ETF sold roughly $7.4 million worth of BioNTech stock. Cathie Wood's ETF has now almost completely sold its entire position in BioNTech. The immunotherapy company faces a projected sales dec…
In Cathie Wood's Ark Genomic Revolution ETF (NYSEMKT: ARKG), as of July 10, the three top holdings are Tempus AI, 10x Genomics, and Twist Bioscience. But digging past the top 10 holdings, there's a $1.8 billion biotech company with a growi…
Cathie Wood's ARK Invest's largest purchase during the last week by value was Elon Musk's Space Exploration Technologies (SPCX [https://seekingalpha.com/symbol/SPCX]), adding a combined 349K shares across ARKK, ARKQ, ARKW and ARKX for ~$52…
Wall Street delivered a strong performance over the past month (as of July 3, 2026).State Street SPDR S&P 500 ETF Trust SPY has gained about 1% over the past month, the Nasdaq-100-based Invesco QQQ Trust, Series 1 QQQ has added about 1.1%…
The biotech industry has held up well this year despite macroeconomic uncertainty, pricing pressures and regulatory challenges. Strong first-quarter earnings, new drug approvals and encouraging clinical trial updates have kept investor sen…
Key Points Interested in iShares Genomics Immunology and Healthcare ETF? Here are five stocks we like better. The field of genomics is on the verge of major breakthroughs that could revolutionize drug creation, disease detection, and more.…
In trading on Thursday, the ARK Genomic Revolution ETF is outperforming other ETFs, up about 7.5% on the day. Components of that ETF showing particular strength include shares of Absci, up about 15.6% and shares of Butterfly Network, up ab…
Cathie Wood’s ARK Investment Management executed a highly active rebalancing strategy for the week ending May 22, 2026. The latest trading data reveals a distinct shift away from certain legacy chipmakers and streaming tech, rotating capit…
Intellia Therapeutics (NTLA) is a clinical-stage biotech firm working on CRISPR-based treatments that try to edit genes directly inside the body – basically aiming to fix diseases at their root with a one-time therapy. But NTLA stock has n…
Joe Raedle Cathie Wood's Ark Invest showed a rotation into large-cap tech and next-generation energy exposure while trimming positions across semiconductors, industrial automation, and space communications names during the last week. The m…
Some IPOs fade into the background after their first week of trading. Alamar Biosciences (ALMR) is not one of them, though. The proteomics company just went public on April 17, and it is already getting a big vote of confidence from Cathie…
Joe Raedle Cathie Wood’s ARK Invest funds executed a broad rotation across technology, healthcare, and industrial names during the last week while markets remained volatile over broader geopolitical tensions between the U.S. and Iran. Buyi…
Since the beginning of 2026, shares of CRISPR Therapeutics (CRSP) are down by about 11%. While that’s not a great start to the year, there are plenty of reasons to be bullish. For one, Cathie Wood can't get enough of CRSP stock, recently p…
Cathie Wood, chief of Ark Investment Management, doesn’t give up on her favorite stocks easily. That’s what she just did, buying one of her top holdings that’s down 15% year-to-date. Wood gained a reputation after the flagship Ark Innovati…
[Zoom headquarters in Silicon Valley] Sundry Photography Nearly four years after Cathie Wood made one of the most eye-catching forecasts of the pandemic-era technology boom, shares of Zoom Communications (ZM [https://seekingalpha.com/symbo…
Palo Alto Investors LP disclosed an increase of 209,523 shares in Dyne Therapeutics(NASDAQ:DYN) in its 13F filing for the quarter ended December 31, 2025, an estimated $3.97 million trade based on quarterly average pricing. What Happened P…
Key Points 209,523-share increase in Dyne Therapeutics; estimated transaction value $3.97 million (based on quarterly average pricing) Quarter-end position in Dyne Therapeutics rose $12.82 million in value, reflecting both trading and stoc…
Cathie Wood’s ARK Invest broadly rotated its portfolios toward AI, autonomous driving, semiconductors, and crypto infrastructure names last week, while cutting exposure to defense, genomics, and software platforms. Significant buying was c…
Just when you had written off biotech stocks as boring, here comes the MIT Technology Review to name its “Three technologies that will shape biotech in 2026.” There’s no moonshot cure for cancer expected just yet, but we can apparently loo…
[Bitcoin 2022 Conference Draws Cryptocurrency Industry Professionals And Investors To Miami] Marco Bello/Getty Images News Cathie Wood’s latest moves entering 2026 focused on early-stage biotechnology firms while cutting exposure to consum…
[Bitcoin 2022 Conference Draws Cryptocurrency Industry Professionals And Investors To Miami] Marco Bello Cathie Wood’s Ark Invest increased exposure to gene-editing names and autonomous mobility companies while further cutting holdings in…
Cathie Wood’s trades often read like a quiet manifesto – what she buys signals confidence, what she trims hints at fading faith. In the week ended Dec. 19, that message was clear. ARK Investment Management leaned harder into AI-led biotech…
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the ARK Genomic Revolution ETF (Symbol: ARKG) where we have detected an approximate $73.5 million dollar outflow…
[Bitcoin 2022 Conference Draws Cryptocurrency Industry Professionals And Investors To Miami] Marco Bello/Getty Images News Cathie Wood’s ARK Investment Management sharply increased its exposure to AI-driven biotechnology and cryptocurrency…
[Bitcoin 2022 Conference Draws Cryptocurrency Industry Professionals And Investors To Miami] Marco Bello Cathie Wood’s ARK Investment Management chopped its holdings in EV maker Tesla (TSLA [https://seekingalpha.com/symbol/TSLA]) and satel…
[Investment. Businessman using laptop and analyzing data with investment growth on stock markets, startups, real estate, technology, and financial trends on global network.] Harsa Maduranga/iStock via Getty Images Cathie Wood’s ARK Invest…
Key Points Cathie Wood aims to identify innovators and invest in them early in their stories. Wood has been regularly adding to her position in this stock, and it’s one of her top holdings.10 stocks we like better than CRISPR Therapeutics…